Diabetic kidney disease is the leading cause of kidney failure worldwide; in the USA, it
accounts for over 50% of individuals entering dialysis or transplant programmes. Unlike …

Although chronic kidney disease is characterized by low glomerular filtration rate (GFR) or
albuminuria, estimated GFR (eGFR) is more widely utilized as a marker of risk profile in …

Background Persons with toxic gain-of-function variants in the gene encoding
apolipoprotein L1 (APOL1) are at greater risk for the development of rapidly progressive …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

Background Sparsentan is a novel, non-immunosuppressive, single-molecule, dual
endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial …

Background In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …

Background Little evidence has been available to support the use of thiazide diuretics to
treat hypertension in patients with advanced chronic kidney disease. Methods We randomly …

This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …

Distinct from the traditional diagnostic/prognostic biomarker (adopted as the indicator of
disease state/process), the therapeutic biomarker (ThMAR) has emerged to be very crucial …

Background Reductions in albuminuria are associated with a subsequent lower risk of
kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin …